Clinical Trial: Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer

Brief Summary: Whether H2 receptor antagonist can prevent thienopyridine-related peptic ulcer remains unclear.

Detailed Summary: The aim of the prospective, randomized study is investigate the efficacy of H2 receptor antagonist in prevention of thienopyridine-related peptic ulcer and gastrointestinal bleeding in patients with an ulcer history. We plan to enroll 236 thienopyridine (clopidogrel or ticlopidine) users with a peptic ulcer history who don't have baseline gastroduodenal ulcers at initial endoscopy . The patients will be randomly assigned to receive either (1) famotidine (40 mg qd) plus thienopyridine used previously or (2) placebo plus thienopyridine treatment alone for 6 months. The ulcer recurrence rate between the treatment gruops will be compared.
Sponsor: Kaohsiung Veterans General Hospital.

Current Primary Outcome: Ulcer recurrence rate [ Time Frame: six month ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Kaohsiung Veterans General Hospital.

Dates:
Date Received: April 12, 2015
Date Started: January 2012
Date Completion: December 2016
Last Updated: February 5, 2016
Last Verified: February 2016